TLDR:
- LabGenius closed a £35 million Series B financing round for therapeutic antibody discovery
- They are using a smart robotic platform powered by machine learning to address challenges in antibody discovery
Full Article:
LabGenius, a drug discovery company, has secured £35 million in Series B funding for the discovery of novel therapeutic antibodies. This brings LabGenius’ total funding to £58 million. The company is utilizing a smart robotic platform called EVA™, powered by machine learning, to design and conduct experiments to identify high-performing antibodies with non-intuitive designs.
LabGenius is focusing on addressing the challenge of on-target, off-tumour toxicity in therapeutic antibodies. They use Multi-Objective Bayesian Optimisation (MOBO) to co-optimize antibodies efficiently across multiple properties. This approach aims to reduce human bias and generate high-performing antibodies with unique designs.
The funding round was led by M Ventures, with participation from Octopus Ventures, LG Corp, and existing investors such as Atomico and Kindred Capital. The new funding will enable LabGenius to expand its platform capabilities and advance a pipeline of multispecific antibodies towards clinical development.
